Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis on October 2, 2023. the sale is scheduled to complete before the end of October 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.015 AUD | -11.76% | -11.76% | -25.00% |
Apr. 10 | Syntara Reaches 50% Recruitment in Phase 2 Trial for Bone Marrow Cancer Treatment | MT |
Feb. 29 | Syntara Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.00% | 11.75M | |
+26.47% | 664B | |
+26.74% | 567B | |
-6.33% | 354B | |
+19.35% | 330B | |
+4.23% | 286B | |
+13.43% | 234B | |
+4.71% | 199B | |
-9.53% | 196B | |
-4.04% | 148B |
- Stock Market
- Equities
- SNT Stock
- News Syntara Limited
- Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis.